Coherus Oncology, Inc. (Form: 4, Received: 06/02/2026 20:30:06)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). ☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Lanfear Dennis M	2. Issuer Name and Ticker or Trading Symbol Coherus Oncology, Inc. [CHRS]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) President & CEO
(Last) (First) (Middle) C/O COHERUS ONCOLOGY, INC. 333 TWIN DOLPHIN DRIVE, SUITE 600	3. Date of Earliest Transaction (MM/DD/YYYY) 5/29/2026
(Street) REDWOOD CITY CALIFORNIA 94065	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person
(City) (State) (Zip/Postal Code)
UNITED STATES
(Country)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$12.7	5/29/2026		D			200,000	⁽¹⁾	8/6/2027	Common Stock	200,000	⁽³⁾	0	D
Stock Option (Right to Buy)	$10.05	5/29/2026		D			400,000	⁽¹⁾	2/1/2028	Common Stock	400,000	⁽³⁾	0	D
Stock Option (Right to Buy)	$12.37	5/29/2026		D			450,000	⁽¹⁾	1/11/2029	Common Stock	450,000	⁽³⁾	0	D
Stock Option (Right to Buy)	$17.73	5/29/2026		D			500,000	⁽¹⁾	1/10/2030	Common Stock	500,000	⁽³⁾	0	D
Stock Option (Right to Buy)	$18.33	5/29/2026		D			500,000	⁽¹⁾	1/23/2031	Common Stock	500,000	⁽³⁾	0	D
Stock Option (Right to Buy)	$17.6	5/29/2026		D			125,000	⁽¹⁾	2/1/2031	Common Stock	125,000	⁽³⁾	0	D
Stock Option (Right to Buy)	$15.94	5/29/2026		D			402,500	⁽¹⁾	1/4/2032	Common Stock	402,500	⁽³⁾	0	D
Stock Option (Right to Buy)	$10.37	5/29/2026		D			402,500	⁽²⁾	1/5/2033	Common Stock	402,500	⁽³⁾	0	D
Stock Option (Right to Buy)	$5.44	5/29/2026		D			225,000	⁽¹⁾	6/13/2033	Common Stock	225,000	⁽³⁾	0	D
Stock Option (Right to Buy)	$1.59 ⁽⁴⁾	5/29/2026		A		200,000		⁽¹⁾	5/29/2036	Common Stock	200,000	⁽³⁾	200,000	D
Stock Option (Right to Buy)	$1.59 ⁽⁴⁾	5/29/2026		A		400,000		⁽¹⁾	5/29/2036	Common Stock	400,000	⁽³⁾	400,000	D
Stock Option (Right to Buy)	$1.59 ⁽⁴⁾	5/29/2026		A		450,000		⁽¹⁾	5/29/2036	Common Stock	450,000	⁽³⁾	450,000	D
Stock Option (Right to Buy)	$1.59 ⁽⁴⁾	5/29/2026		A		500,000		⁽¹⁾	5/29/2036	Common Stock	500,000	⁽³⁾	500,000	D
Stock Option (Right to Buy)	$1.59 ⁽⁴⁾	5/29/2026		A		500,000		⁽¹⁾	5/29/2036	Common Stock	500,000	⁽³⁾	500,000	D
Stock Option (Right to Buy)	$1.59 ⁽⁴⁾	5/29/2026		A		125,000		⁽¹⁾	5/29/2036	Common Stock	125,000	⁽³⁾	125,000	D
Stock Option (Right to Buy)	$1.59 ⁽⁴⁾	5/29/2026		A		402,500		⁽¹⁾	5/29/2036	Common Stock	402,500	⁽³⁾	402,500	D
Stock Option (Right to Buy)	$1.59 ⁽⁴⁾	5/29/2026		A		402,500		⁽²⁾	5/29/2036	Common Stock	402,500	⁽³⁾	402,500	D
Stock Option (Right to Buy)	$1.59 ⁽⁴⁾	5/29/2026		A		225,000		⁽¹⁾	5/29/2036	Common Stock	225,000	⁽³⁾	225,000	D

Explanation of Responses:
(1)	The option is fully vested and exercisable.
(2)	The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 5, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
(3)	On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged.
(4)	On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Lanfear Dennis M C/O COHERUS ONCOLOGY, INC. 333 TWIN DOLPHIN DRIVE, SUITE 600 REDWOOD CITY CALIFORNIA 94065 UNITED STATES	X		President & CEO

Signatures
/s/ Bryan McMichael, as Attorney-in-Fact for Dennis M. Lanfear		6/2/2026
^**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
* Form 4: SEC 1474 (03-26).